{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:24Z","timestamp":1792460304933,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2026-A-009, CSH-2026-C-030"],"award-info":[{"award-number":["CSH-2026-A-009, CSH-2026-C-030"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2026-F-003"],"award-info":[{"award-number":["CSH-2026-F-003"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-040-026-MY2 and NSTC 114-2622-B-040-001"],"award-info":[{"award-number":["NSTC 113-2314-B-040-026-MY2 and NSTC 114-2622-B-040-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04488-8","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:26:22Z","timestamp":1783135582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation"],"prefix":"10.1007","volume":"75","author":[{"given":"Yu-Jung","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Chia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Meyerowitz-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pen-Hua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"1","key":"4488_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"4488_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"key":"4488_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011258","author":"J Dent","year":"2025","unstructured":"Dent J, Jorge M, Sobrevilla N, Uldrick TS, Adoubi I, Bajpai J et al (2025) Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-011258","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4488_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1017\/S002966511500419X","volume":"75","author":"AM Ryan","year":"2016","unstructured":"Ryan AM, Power DG, Daly L, Cushen SJ, N\u00ed Bhuachalla \u0112, Prado CM (2016) Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 75(2):199\u2013211","journal-title":"Proc Nutr Soc"},{"key":"4488_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutos.2025.100620","volume":"65","author":"C Martinelli","year":"2026","unstructured":"Martinelli C, Ercoli A, Alfano L, Pentimalli F, Mazzarotti G, Ferrantelli G et al (2026) Cachexia, sarcopenia, malnutrition and their impact on survival, treatment toxicities, and quality of life in locally advanced cervical cancer patients undergoing concomitant chemoradiotherapy: a scoping review. Clin Nutr Open Sci 65:100620","journal-title":"Clin Nutr Open Sci"},{"issue":"5","key":"4488_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11154-023-09829-x","volume":"24","author":"P Portincasa","year":"2023","unstructured":"Portincasa P, Fr\u00fchbeck G (2023) Phenotyping the obesities: Reality or utopia? Rev Endocr Metab Disord 24(5):767\u2013773","journal-title":"Rev Endocr Metab Disord"},{"key":"4488_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102253","volume":"101","author":"J Bolte","year":"2025","unstructured":"Bolte J, Smelter AA, Norton L (2025) Are we giving too much weight to lean mass loss? Mol Metab 101:102253","journal-title":"Mol Metab"},{"issue":"8","key":"4488_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/07853890.2018.1511918","volume":"50","author":"CM Prado","year":"2018","unstructured":"Prado CM, Purcell SA, Alish C, Pereira SL, Deutz NE, Heyland DK et al (2018) Implications of low muscle mass across the continuum of care: a narrative review. Ann Med 50(8):675\u2013693","journal-title":"Ann Med"},{"issue":"36","key":"4488_CR9","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126","journal-title":"J Clin Oncol"},{"issue":"17","key":"4488_CR10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"11","key":"4488_CR11","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1111\/dom.15869","volume":"26","author":"YN Huang","year":"2024","unstructured":"Huang YN, Liao WL, Huang JY, Lin YJ, Yang SF, Huang CC et al (2024) Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: a global retrospective cohort study. Diabetes Obes Metab 26(11):5222\u20135232","journal-title":"Diabetes Obes Metab"},{"key":"4488_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01183-8","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ (2025) GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/s41573-025-01183-8","journal-title":"Nat Rev Drug Discov"},{"key":"4488_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","volume":"27","author":"RW Thomsen","year":"2025","unstructured":"Thomsen RW, Mailhac A, L\u00f8hde JB, Potteg\u00e5rd A (2025) Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab 27:66\u201388","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"4488_CR14","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"10","key":"4488_CR15","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","volume":"49","author":"A Ismaiel","year":"2025","unstructured":"Ismaiel A, Scarlata GGM, Boitos I, Leucuta DC, Popa SL, Al Srouji N et al (2025) Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes (Lond) 49(10):1946\u20131957","journal-title":"Int J Obes (Lond)"},{"issue":"Suppl 4","key":"4488_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL (2024) Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 26(Suppl 4):16\u201327","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"4488_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","volume":"11","author":"H Dai","year":"2025","unstructured":"Dai H, Li Y, Lee YA, Lu Y, George TJ, Donahoo WT et al (2025) GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol 11(10):1186\u20131193","journal-title":"JAMA Oncol"},{"key":"4488_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.113073","volume":"231","author":"S-H Chan","year":"2026","unstructured":"Chan S-H, Li P-Y, Li P-H, Lin Y-J, Wang W-H, Huang Y-N et al (2026) GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and immune-related adverse events across cancer types in people with type 2 diabetes: a target-trial emulation. Diabetes Res Clin Pract 231:113073","journal-title":"Diabetes Res Clin Pract"},{"key":"4488_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202518813","author":"YN Huang","year":"2025","unstructured":"Huang YN, Tsou MY, Li PH, Chen JC, Liu YL, Meyerowitz-Katz G et al (2025) Effectiveness of pre-transplant dual GLP-1 receptor agonist and SGLT2 inhibitor therapy on all-cause mortality in organ transplantation candidates with obesity and type 2 diabetes: a target-trial emulation. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202518813","journal-title":"Adv Sci"},{"issue":"4","key":"4488_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamainternmed.2024.8129","volume":"185","author":"BN Dib","year":"2025","unstructured":"Dib BN, Swanson SA (2025) Emulating a target trial using observational data. JAMA Intern Med 185(4):459\u2013460","journal-title":"JAMA Intern Med"},{"key":"4488_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, Ruyeras JMMJ, Aparece JP, Bantayan NRB et al (2024) Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol 18:100679","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"4488_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02986-0","volume":"24","author":"E Tartaglia","year":"2025","unstructured":"Tartaglia E, Bucci T, Rossi M, Rigutini AG, Askarinejad A, Alam U et al (2025) Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network. Cardiovasc Diabetol 24(1):438","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"4488_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y et al (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 182(5):513\u2013519","journal-title":"JAMA Intern Med"},{"key":"4488_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115170","volume":"216","author":"CH Chiang","year":"2025","unstructured":"Chiang CH, Song J, Chi KY, Chang YC, Xanthavanij N, Chang Y et al (2025) Glucagon-like peptide-1 agonists reduce cardiovascular events in cancer patients on immune checkpoint inhibitors. Eur J Cancer 216:115170","journal-title":"Eur J Cancer"},{"issue":"16_suppl","key":"4488_CR25","doi-asserted-by":"publisher","first-page":"11174","DOI":"10.1200\/JCO.2025.43.16_suppl.11174","volume":"43","author":"D Mukherjee","year":"2025","unstructured":"Mukherjee D, Walsh D, Alqahtani SA, Krishnan A (2025) Efficacy GLP-1 agonists, SGLT-2 inhibitors and other glucose-lowering medications on cardiorenal outcomes in patients with diabetes and cancer on immune checkpoint therapy. J Clin Oncol 43(16_suppl):11174","journal-title":"J Clin Oncol"},{"issue":"1","key":"4488_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-01066-4","volume":"5","author":"Y-N Huang","year":"2025","unstructured":"Huang Y-N, Chen J-C, Li P-H, Hsu M-Y, Cheng C-W, Meyerowitz-Katz G et al (2025) Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity. Commun Med 5(1):329","journal-title":"Commun Med"},{"issue":"1","key":"4488_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2337\/db23-0356","volume":"73","author":"M Mashayekhi","year":"2024","unstructured":"Mashayekhi M, Nian H, Mayfield D, Devin JK, Gamboa JL, Yu C et al (2024) Weight loss-independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes. Diabetes 73(1):38\u201350","journal-title":"Diabetes"},{"issue":"1","key":"4488_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):234","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4488_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70030","volume":"6","author":"T Wang","year":"2020","unstructured":"Wang T, Zhou D, Hong Z (2020) Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions. MedComm 6(1):e70030","journal-title":"MedComm"},{"issue":"5","key":"4488_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s11154-025-09968-3","volume":"26","author":"J Mesinovic","year":"2025","unstructured":"Mesinovic J, Hurst C, Leung GKW, Ryan JR, Daly RM, Scott D (2025) Exercise and dietary recommendations to preserve musculoskeletal health during weight loss in adults with obesity: a practical guide. Rev Endocr Metab Disord 26(5):785\u2013803","journal-title":"Rev Endocr Metab Disord"},{"key":"4488_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos ED, Bakris GL, Rodbard HW, Tuttle KR (2023) Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am J Prev Cardiol 14:100502","journal-title":"Am J Prev Cardiol"},{"key":"4488_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117668","volume":"181","author":"I Stanisavljevic","year":"2024","unstructured":"Stanisavljevic I, Pavlovic S, Simovic Markovic B, Jurisevic M, Krajnovic T, Mijatovic S et al (2024) Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity. Biomed Pharmacother 181:117668","journal-title":"Biomed Pharmacother"},{"key":"4488_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbrc.2022.06.052","volume":"619","author":"D Chen","year":"2022","unstructured":"Chen D, Li Q, Liang H, Huang L, Zhou H, Zheng X et al (2022) Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps. Biochem Biophys Res Commun 619:97\u2013103","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"4488_CR34","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1039\/D5FO03273C","volume":"16","author":"Y Luo","year":"2025","unstructured":"Luo Y, Xu H, Zhao Y, Yang B, Zhang Y (2025) GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies. Food Funct 16(23):8943\u20138964","journal-title":"Food Funct"},{"issue":"1","key":"4488_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13046-024-03263-w","volume":"44","author":"C Cencioni","year":"2025","unstructured":"Cencioni C, Malatesta S, Vigiano Benedetti V, Licursi V, Perfetto L, Conte F et al (2025) The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. J Exp Clin Cancer Res 44(1):18","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04488-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04488-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04488-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:48:55Z","timestamp":1790293735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04488-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4488"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04488-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9412701\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yu-Jung Lin, Pei-Yun Li, Shao-Chia Chen, Gideon Meyerowitz-Katz, Yu-Nan Huang, Pen-Hua Su declare no competing interests. The funding bodies had no role in the study design, data collection, analysis, interpretation, or manuscript preparation. The authors affirm independence in the conduct of this research and in the decision to publish.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This cohort study used the TriNetX US Collaborative Network, a federated research platform that integrates electronic health record (EHR) data from participating healthcare organizations. Records accessed through TriNetX are de-identified in accordance with the HIPAA Privacy Rule, with de-identification attested by expert determination. Direct patient identifiers are not available, and individual-level chart review is not supported within the platform. The protocol was approved by the Institutional Review Board of Taipei Tzu Chi Hospital (14-IRB154) and aligned with the principles of the Declaration of Helsinki. The analytic dataset was derived from the TriNetX US Collaborative Network, which comprises de-identified EHR data contributed by approximately 70 healthcare organizations in the USA.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"235"}}